

Special Issue

Genitourinary Cancer: The Latest Advances in Diagnosis and Therapy

Message from the Guest Editor

This Special Issue aims to gather an article collection of scientific excellence in the field of genitourinary cancer. This includes a broad-based group of genitourinary (GU) cancers in the urinary systems of both men and women. In recent years, there have been substantial advancements in both the diagnostics and therapy of entities in this group, we find it of crucial interest for a broad medical audience to present clinical and basic research elucidating novel tumor biology-related data, as well as their potential and recognized clinical and therapeutic impact. We encourage researchers to apply original research studies and rare case studies with a review of the literature as well as focused review articles since, there has been significant progress in the understanding and management of genitourinary tumors, with the introduction of new surgical options and the introduction of new therapy approaches, which without doubt are revolutionizing the management of tumor entities in this field. Articles describing novelties in prevention, epidemiology, detection, diagnosis, and new data from diverse therapeutically applicable options as well as basic research studies are welcomed.

Guest Editor

Dr. Sanja Štifter-Vretenar

Department of Pathology, Århus University Hospital, DK-8200 Århus, Denmark

Deadline for manuscript submissions

closed (30 October 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/195603

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)